Cell Microsystems, a provider of innovative tools and scalable solutions for the sorting and isolation of single cells, announced today it is accelerating the development of new products based on its CellRaft™ Technology and expanding their availability in the marketplace. The CellRaft Technology, which allows researchers to easily sort cells under standard culture conditions resulting in unperturbed phenotypes and high viability, will now be available to researchers and laboratories from multiple sources. Previously, products based on the CellRaft Technology were sold exclusively by QIAGEN under the terms of a 2015 agreement. Going forward, Cell Microsystems will independently commercialize new and existing products and systems that provide optimal application-specific performance to meet the needs of researchers for both RNA/DNA sequencing and clonal propagation applications such as CRISPR/Cas9 transfection.
“We are looking forward to making the CellRaft Technology available to additional partners and new customers,” said Gary Pace, CEO at Cell Microsystems. “Not only will this further accelerate market adoption of existing products, but also allows us to commercialize new products, product applications, and systems, including automated isolation and recovery of single cells from new array formats.”
“Single cell analysis solutions have seen rapid adoption in many applications in research. Adding further workflow options is in the best interest of bringing the CellRaft Technology to researchers,” said Michael Kazinski, Head of Global Product Management for Sample Technologies in the Life Sciences Business Area at QIAGEN.
The two companies have developed a set of FAQs to assist existing and new customers in understanding the transition. See www.cellmicrosystems.com/news/.
About Cell Microsystems
Cell Microsystems is an early growth stage company that develops, manufactures, and markets innovative products for single cell biology. The Company’s proprietary CellRaft™ Technology enables high-efficiency sorting and isolation of single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled with the Company’s automated imaging platform, a user can select a cell in real-time and ‘track and trace’ that cell through imaging, collection and downstream analysis. By sorting during real-time imaging, no cells are wasted enabling single cell isolation from even small, precious samples. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab. For more information, visit: https://cellmicrosystems.com/.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA), a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2017, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.QIAGEN.com.